# US 8,785,713 B2 · Compositions with reactive ingredients, and wound dressings, apparatuses, and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,785,713 B2
- Document ID: US8785713B2
- Status: Granted
- Kind: B2
- Application number: 13/085,041
- Filed: 2011-04-12
- Published: 2011-10-20
- Granted: 2014-07-22
- Earliest claimed: 2010-04-13
- Assignees: KCI Licensing, Inc.
- Applicants: Kz Hong; Shannon C. Ingram; Dmitry Zimnitsky; Justin Alexander Long; Richard M. Kazala, Jr.; Hugo Ramirez
- Inventors: Kz Hong; Shannon C. Ingram; Dmitry Zimnitsky; Justin Alexander Long; Richard M. Kazala, Jr.; Hugo Ramirez
- Web page: https://patentgrep.com/patent/US8785713B2

## CPC

- A61M 1/92: {with liquid supply means}
- A61F 13/00072: {Packaging of dressings}
- A61F 13/05: specially adapted for use with sub-pressure or over-pressure therapy, wound drainage or wound irrigation, e.g. for use with negative-pressure wound therapy [NPWT]
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61L 15/425: {Porous materials, e.g. foams or sponges}
- A61L 26/0095: {Composite materials, i.e. containing one material dispersed in a matrix of the same or different material}
- A61M 1/85: {with gas or fluid supply means, e.g. for supplying rinsing fluids or anticoagulants (for negative pressure wound therapy A61M1/92, A61M1/94; combined with tracheal tubes A61M16/0463; dental instruments with combined rinsing and aspirating A61C17/0208)}
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 31/02: Local antiseptics
- A61F 2013/0017: {possibility of applying fluid}
- A61F 2013/00174: {possibility of applying pressure}
- A61F 2013/00536: {for draining or irrigating wounds}
- A61F 2013/0091: {with disinfecting or anaesthetics means, e.g. anti-mycrobic}
- A61M 1/915: {Constructional details of the pressure distribution manifold}
- A61M 35/00: Devices for applying media, e.g. remedies, on the human body (devices for handling toiletry or cosmetic substances A45D; absorbent pads, e.g. swabs, A61F13/15)
- A61M 2205/7536: allowing gas passage, but preventing liquid passage, e.g. liquophobic, hydrophobic, water-repellent membranes
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Wound dressings and wound inserts comprising substantially dry reactive agents, methods of forming wound inserts comprising dry reactive agents, and wound-treatment methods.

## Claims

### Claim 1

A wound insert, comprising:
an open-celled foam configured to be disposed between a wound of a patient and a drape configured to be coupled to skin adjacent the wound; and
a reactive agent disposed within the foam, and configured to be inert in the absence of an activating fluid and to exhibit antimicrobial properties in the presence of an activating fluid;
wherein the reactive agent is configured to react with water to release hypochlorite ion and/or form hypochlorous acid.

### Claim 2 (depends on 1)

The wound insert of claim 1, where the reactive agent comprises a hypochlorite salt defined by M(OCl)n, where n=1 if M is K+, Li+, or Na+, and where n=2 if M is Ca2+ or Mg2+.

### Claim 3 (depends on 1)

The wound insert of claim 1, further comprising
a biocompatible suspension agent that couples the reactive agent to the foam and optionally at least partially encapsulates the reactive agent.

### Claim 4 (depends on 3)

The wound insert of claim 3, where the suspension agent comprises polycaprolactone (PCL).

### Claim 5 (depends on 3)

The wound insert of claim 3, where the wound insert is configured to release a hypochlorite ion in the presence of a volume of activating liquid such that after release the volume of activating liquid will have a concentration of hypochlorite ion between 0.7 and 20 millimolar (mM).

### Claim 6 (depends on 5)

The wound insert of claim 5, where the wound insert is configured to release a hypochlorite ion in the presence of each of three or more sequential volumes of activating liquid such that after release each sequential volume of activating liquid will have a concentration of hypochlorite ion between 0.7 and 20 millimolar (mM).

### Claim 7 (depends on 3)

The wound insert of claim 3, where the foam comprises silicone.

### Claim 8 (depends on 3)

The wound insert of claim 3, further comprising:
a second open-celled foam that is not coupled to the reactive agent;
where the first open-celled foam is configured to be inert in the present of the reactive agent, and forms a first layer of the wound insert; and
where the second open-celled foam forms a second layer of the wound insert, and is coupled to the first open-celled foam.

### Claim 9

A wound dressing comprising:
a wound insert comprising:
an open-celled foam configured to be disposed between a wound of a patient and a drape configured to be coupled to skin adjacent the wound;
a reactive agent disposed within the foam, and configured to be inert in the absence of an activating fluid and to exhibit antimicrobial properties in the presence of an activating fluid;
wherein the reactive agent is configured to react with water to release hypochlorite ion and/or form hypochlorous acid; and
a biocompatible suspension agent that couples the reactive agent to the foam and optionally at least partially encapsulates the reactive agent; and
a drape configured to be coupled to skin adjacent a wound of a patient.

### Claim 10

A wound-treatment apparatus comprising:
a wound insert comprising
an open-celled foam configured to be disposed between a wound of a patient and a drape configured to be coupled to skin adjacent the wound;
a reactive agent disposed within the foam, and configured to be inert in the absence of an activating fluid and to exhibit antimicrobial properties in the presence of an activating fluid;
wherein the reactive agent is configured to react with water to release hypochlorite ion and/or form hypochlorous acid; and
a biocompatible suspension agent that couples the reactive agent to the foam and optionally at least partially encapsulates the reactive agent;
a drape configured to be coupled to skin adjacent a wound of a patient; and
a fluid source configured to be coupled to the wound dressing such that the fluid source is actuatable to deliver a fluid to the wound dressing.

### Claim 11 (depends on 10)

The apparatus of claim 10, further comprising:
a vacuum source configured to be coupled to the wound dressing such that the vacuum source is actuatable to apply negative pressure to the wound dressing.

### Claim 12

A method comprising:
adding hypochlorite salt particles to a solution such that the solution and hypochlorite salt form a slurry, the solution comprising a polymer and a liquid that is a solvent of the polymer but not a solvent of the hypochlorite salt;
substantially removing the liquid from the slurry such that at least a portion of the hypochlorite salt particles are at least partially encapsulated by the polymer.

### Claim 13 (depends on 12)

The method of claim 12, where the hypochlorite salt is defined by M(OCl)n, where n=1 if M is K+, Li+, or Na+, and where n=2 if M is Ca2+ or Mg2+.

### Claim 14 (depends on 13)

The method of claim 13, where the hypochlorite salt is defined by Ca(OCl)2.

### Claim 15 (depends on 12)

The method of claim 12, where the polymer is biocompatible and optionally biodegradable.

### Claim 16 (depends on 15)

The method of claim 15, where the polymer is not water soluble.

### Claim 17 (depends on 16)

The method of claim 16, where the polymer comprises polycaprolactone (PCL).

### Claim 18 (depends on 12)

The method of claim 12, where the solvent is non-aqueous.

### Claim 19 (depends on 18)

The method of claim 18, where the solvent comprises at least one of Dichloromethane (DCM or methylene chloride), Tetrahydrofuran (THF), or Cyclohexane.

### Claim 20 (depends on 12)

The method of claim 12, further comprising:
disposing, prior to substantially removing the liquid, a foam in the slurry such that hypochlorite salt particles and polymer are dispersed within the foam.

### Claim 21 (depends on 20)

The method of claim 20, further comprising:
reducing, prior to adding the hypochlorite salt particles into the solution, the size of the hypochlorite salt particles such that a majority of the hypochlorite salt particles have a size at or below a target size.

### Claim 22 (depends on 21)

The method of claim 21, where the target size is 180 microns.